AI Drug Discovery for Pharma and Biotech

Drug discovery

1

drug

With orphan designation

Overview

CAR T cell therapy-associated cytokine release syndrome (CRS) is a systemic inflammatory response triggered by rapid immune activation post-infusion, characterized by elevated cytokines (e.g., IL-6, IFN-γ) and clinical manifestations ranging from fever to life-threatening capillary leak syndrome. It occurs in 45-90% of patients, typically within days of treatment. Management includes IL-6 blockade (tocilizumab) and corticosteroids, with severity-dependent escalation to critical care [1][2][6][12].

Population

Primarily affects adults with relapsed/refractory hematologic malignancies (e.g., DLBCL, ALL, multiple myeloma), with incidence varying by CAR-T product (45% for lisocabtagene maraleucel vs. 90% for axicabtagene ciloleucel) [2][7][9].

Burden

  • Median hospital charges exceed $530,000 per admission, with 12% requiring ICU care [9].

  • Mortality reaches 10% in severe cases, driven by multi-organ failure [9][12].

Therapies

  • First-line: Tocilizumab (IL-6R antagonist) for moderate-severe CRS [1][6][12].

  • Corticosteroids for refractory cases or concurrent neurotoxicity [13][15].

  • Emerging approaches: Kinase inhibitors, cytokine-neutralizing CAR-T cells, and computational models for personalized dosing [3][8][11].

Categories: rare systemic and rheumatological diseases

Research Papers

163 drug discovery papers about CAR T cell therapy-associated cytokine release syndrome, with 3 first-in-class and 2 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

163 drug discovery papers about CAR T cell therapy-associated cytokine release syndrome, with 3 first-in-class and 2 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

antibodies
2026-06-22 | Chimeric antigen receptor-T cell therapy-induced cardiotoxicity: Pathophysiological mechanisms and pharmacological intervention strategies

Chimeric antigen receptor (CAR)-T cell therapy has emerged as a revolutionary treatment for hematologic malignancies and solid tumors. Multiple approved products and ongoing clinical trials have demonstrated its remarkable antitumor efficacy. However, its clinical application is severely limited by prominent cardiotoxicity, which is closely associated with high morbidity and mortality, posing an urgent clinical challenge. This review systematically elucidates the pathophysiological mechanisms underlying CAR-T cell therapy-induced cardiotoxicity, which can be primarily categorized into acute and long-term adverse effects. Acute cardiotoxicity is driven by cytokine release syndrome (CRS) through macrophage and monocyte activation, endothelial dysfunction, and subsequent myocardial injury, leading to hypotension, reduced left ventricular ejection fraction, and cardiac arrhythmias. Long-term cardiotoxicity is mainly caused by B-cell aplasia-induced immune deficiency and secondary hemophagocytic lymphohistiocytosis, which trigger infectious complications, myocardial ischemia, and apoptosis. We have further summarized clinical pharmacological interventions for such cardiotoxicity, including interleukin (IL)-6 receptor antagonists (tocilizumab), interferon-γ inhibitors (emapalumab), and Janus kinase inhibitors (ruxolitinib). However, none of these drugs can completely alleviate CRS or CAR-T cell therapy-induced cardiotoxicity in all patients. Preclinical agents targeting inflammatory cytokines (IL-1β, tumor necrosis factor-α) and signaling pathways have shown efficacy in ameliorating cardiotoxicity in various animal models. These findings provide novel directions and drug candidates for the treatment of CAR-T cell therapy-induced myocardial toxicity. This review provides a comprehensive theoretical basis for optimizing cardiovascular safety management and developing novel targeted interventions for CAR-T cell therapy.

Open article ↗



2026-05-26 | Characterization of CAR-T cell factors that contribute to myeloid cell activation

Chimeric antigen receptor (CAR) T cell therapies have shown remarkable success in the treatment of hematologic cancers; however, their use is often accompanied by inflammatory toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). These toxicities, ranging from mild to life-threatening, are partly driven by bystander myeloid cell activation (BMCA) and the subsequent release of pro-inflammatory cytokines such as IL-6 and IL-1β. Although previous studies have described the individual contributions of GM-CSF, IFN-γ, and TNFα secreted by CAR-T cells, a comprehensive characterization of CAR-T-derived inflammatory factors has been lacking. In this study, we characterized the soluble factors secreted by activated CAR-T cells derived from human peripheral blood and assessed their role in BMCA. Comparative cytokine analyses across human T cell subsets, including CAR-T cells, identified multiple candidates involved in BMCA. Antibody-mediated neutralization confirmed that four factors, GM-CSF, IFN-γ, TNFα, and GPIbα, play dominant roles in driving BMCA. Furthermore, siRNA-mediated knockdown of these factors in CAR-T cells significantly reduced BMCA without impairing their anti-tumor activity. These findings are consistent with prior reports on the inflammatory roles of GM-CSF, IFN-γ, and TNFα during CAR-T cell therapy and, importantly, identify GPIbα as a previously unrecognized contributor to CAR-T-associated inflammatory toxicities. Targeting these factors through antibody blockade or genetic modification may represent a promising strategy to mitigate inflammatory toxicities and improve the safety of CAR-T cell therapies.

Open article ↗



2026-03-04 | Emapalumab in pediatric patients with high-grade cytokine release syndrome associated with CAR T-cell therapy

Background Chimeric antigen receptor T (CAR-T) cell therapy significantly improves the prognosis of a variety of hematological malignancies; however, its broader application in clinical practice is hindered by adverse events, particularly cytokine release syndrome (CRS). Moreover, the selection of treatment strategies for patients with high-grade CRS must be meticulously tailored. Emapalumab, a fully human IgG1 monoclonal antibody targeting IFN-γ, has been proposed to have clinical benefit in CRS. Methods In this retrospective study, we conducted a comprehensive analysis of clinical and laboratory parameters in 38 pediatric patients who failed low-dose glucocorticoids monotherapy, tocilizumab monotherapy or glucocorticoid-tocilizumab combination therapy, following treatment with investigational CAR-T products. Results Emapalumab significantly improved both clinical symptoms and laboratory parameters. The rapid decrease in mean temperature (39.61 vs. 38.38°C, P < 0.001) and levels of inflammatory markers including IL-2 (32.35 vs. 11.94 pg/ml, P < 0.001), IL-10 (222.29 vs. 86.09 pg/ml, P = 0.018), TNF-α (4.17 vs. 2.94 pg/ml, P = 0.032), and IFN-γ (21984.11 vs. 674.87 pg/ml, P < 0.001) indicated the remarkable scavenging efficacy of emapalumab against cytokine storm following CAR-T therapy. Additionally, both mean CAR-T cell counts (549.95 vs. 8.16 cell/μl, P < 0.001) and the ratio of CAR-T to CD3+ (11.3% vs. 36.54%, P < 0.001) in peripheral blood increased significantly, demonstrating that the administration of emapalumab didn’t seem to have a significant negative impact on the proliferation of CAR-T cells. The median EFS and OS were both not reached, with an EFS rate of 76.9% (95%CI, 63.8-92.6) and with an OS rate of 80.1% (95% CI, 67.7-94.6) at 6 months. Throughout the treatment course, no direct evidence of emapalumab-related safety risks was observed. Conclusion Emapalumab seems to serve as an effective salvage therapy for patients experiencing high-grade CRS with inadequate response to low-dose glucocorticoids and/or tocilizumab following CAR-T therapy. These data supported the use of emapalumab in high-grade CRS as well as provide rationale for future prospective studies.

Open article ↗



2026-02-27 | CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma in a nonagenarian patient

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the management of relapsed/refractory large B-cell lymphoma. However, evidence in the ultra-elderly population remains scarce. We report a 90-year-old woman with relapsed/refractory diffuse large B-cell lymphoma transformed from follicular lymphoma who received lisocabtagene maraleucel. Despite advanced age, preserved cognition, intact instrumental activities of daily living, and acceptable organ reserve supported her candidacy for CAR T-cell therapy. Cytokine release syndrome (CRS) developed as grade 1 (day 1, 38.0 °C) and grade 2 (day 3, hypoxemia to 6 L/min), which resolved after early tocilizumab and dexamethasone. No immune effector cell-associated neurotoxicity syndrome or infectious complications occurred. Grade 2-4 cytopenia persisted transiently but was managed with supportive care, and she was discharged on day 28. To our knowledge, this represents the first reported case of a nonagenarian Asian patient successfully treated with CAR T-cell therapy, highlighting the feasibility and tolerability of this approach and emphasizing the importance of geriatric assessment and prompt CRS management for safe delivery in the very elderly.

Open article ↗



2026-01-01 | Fanning the flames: IFN-γ fuels CAR-T inflammation and cytopenia

Chimeric antigen receptor T cell (CAR-T) therapy has transformed the treatment of hematologic malignancies, yet, severe inflammatory toxicities continue to limit its broader use. In this issue of the JCI, Goala et al. uncovered a mechanistic link between IFN-γ-driven inflammation and disrupted neutrophil homeostasis, revealing that cytokine release syndrome (CRS) and immune cell-associated hematologic toxicity (ICAHT) stem from a shared biological pathway. Using IL-2Ra-deficient mice and patient samples, they showed that IFN-γ suppressed IL-17A and granulocyte colony-stimulating factor (G-CSF), disrupting granulopoiesis and neutrophil survival. Strikingly, IFN-γ blockade eased both CRS and neutropenia without diminishing CAR-T efficacy, suggesting a path toward safer, better-tolerated cell therapies.

Open article ↗



small molecules
2026-05-05 | Extracorporeal blood purification in the management of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a case report

Chimeric antigen receptor T-cell (CAR-T) therapy is associated with potentially severe toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). We report a case of a 32-year-old man with refractory diffuse large B-cell lymphoma who developed severe ICANS after axicabtagene ciloleucel infusion despite standard treatment with corticosteroids, tocilizumab, anakinra, and supportive therapy. Because of rapid clinical deterioration, extracorporeal blood purification with CytoSorb was initiated. The treatment was followed by rapid neurological and hemodynamic improvement, reduction of inflammatory markers, and transfer from the intensive care unit to the hematology ward. CAR-T cell expansion, monitored by droplet digital PCR, was preserved after cytokine adsorption. This case suggests that extracorporeal blood purification may be a feasible rescue strategy for severe CAR-T-related neurotoxicity without compromising CAR-T cell activity.

Open article ↗



2026-03-12 | The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy

Chimeric antigen receptor T (CAR T)-cell therapy is revolutionizing cancer treatment in hematologic malignancies, but challenges related to the tumor microenvironment have hindered CAR T success, especially in solid tumors. Myeloid cells in particular have been implicated in CAR T efficacy. In this review, we discuss the roles of myeloid cells in CAR T-associated toxicities, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, along with strategies to treat these toxicities by modulating myeloid cells. The review also explores myeloid cell-mediated suppression or enhancement of CAR T function. Finally, strategies used to target myeloid cells in combination with CAR T-cell therapy will be investigated.

Open article ↗



2026-01-01 | Next-generation CAR-T combinations: Integrating nanomedicine, metabolic reprogramming, and AI for solid tumor targeting

Background Chimeric Antigen Receptor (CAR)-T cell therapy has demonstrated remarkable clinical success in hematological malignancies; however, its translation to solid tumors remains limited due to the hostile tumor microenvironment (TME), characterized by physical barriers, immunosuppression, metabolic competition, and treatment-limiting toxicities such as Cytokine Release Syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Purpose This review aims to critically evaluate next-generation combination strategies that enhance CAR-T efficacy in solid tumors, with particular emphasis on phytochemicals and natural small molecules as immunometabolic modulators within multimodal therapeutic frameworks. Study Design This is a narrative and mechanism-oriented review integrating evidence from immunotherapy, pharmacology, nanomedicine, and computational biology. Methods Relevant literature was systematically examined to analyze emerging approaches that combine CAR-T therapy with nanotechnology-enabled delivery systems, phytochemical-based metabolic modulation, and artificial intelligence-driven network pharmacology. Mechanistic pathways including AMPK-mTOR-SIRT1 signaling, NF-κB activation, STAT3 signaling, and NLRP3 inflammasome regulation were evaluated in the context of CAR-T persistence, metabolic fitness, and toxicity mitigation. Results Evidence indicates that localized nanotechnology platforms such as “backpack” nanoparticles improve CAR-T trafficking and reduce systemic toxicity. Phytochemicals including resveratrol, berberine, curcumin, and baicalin function as metabolic regulators that promote mitochondrial fitness, shift T-cell metabolism toward oxidative phosphorylation, and attenuate hyperinflammatory signaling underlying CRS. Artificial intelligence and network pharmacology approaches further enable rational identification of synergistic combinations and predictive responder stratification. Conclusion Multimodal precision strategies integrating nanotechnology, phytochemical immunometabolic modulation, and computational design represent promising avenues to overcome solid tumor resistance to CAR-T therapy. Repositioning natural small molecules as mechanistic immunopharmacological adjuvants may enhance therapeutic durability while reducing toxicity, supporting their translational potential in solid tumor immunotherapy.

Open article ↗



2025-11-02 | High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T)

Background: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated substantial efficacy in relapsed and/or refractory multiple myeloma. While toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) have been well characterized, the incidence and clinical consequences of the coagulopathy associated with CRS remain underexplored. Methods: We conducted a prospective analysis of 108 adult patients with multiple myeloma or light chain amyloidosis treated with the academic anti-BCMA CAR-T HBI0101 in a single-center trial (NCT04720313). Coagulopathy was evaluated via serial fibrinogen measurements, with hypofibrinogenemia defined as <200 mg/dL and severe coagulopathy as <100 mg/dL. Laboratory markers, tocilizumab and blood product use, and thrombotic and bleeding complications were recorded. Patients received a short (3-day) or extended course of enoxaparin thromboprophylaxis as well as fresh frozen plasma in cases of severe coagulopathy. Results: CRS grades 1-3 occurred in 100 patients (93%). Hypofibrinogenemia was observed in 79 patients (73%), including 20 (19%) with severe coagulopathy. Fibrinogen levels were significantly associated with CRS severity (p < 0.001), number of tocilizumab doses (p < 0.001), peak levels of the inflammation markers LDH (p = 0.001) and ferritin (p = 0.006), and neutropenia (p = 0.33). Five thrombotic events (4.6%) and three minor bleeding events (2.7%) occurred within 3 months post-CAR-T infusion and were not associated with degree of coagulopathy or CRS. No cases of major bleeding or fatal thrombosis occurred. Conclusions: CRS-related coagulopathy is common following BCMA-targeted CAR-T treatment and correlates closely with CRS severity. Despite the high rate of laboratory coagulopathy, thrombosis and bleeding events were infrequent, suggesting the benefit of the prophylactic strategies used.

Open article ↗



2025-11-01 | Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma

Corticosteroids are commonly used to manage cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor (CAR) T-cell therapy, and yet, their dose-specific impact on outcomes remains uncertain. We retrospectively evaluated 276 adults with large B-cell lymphoma (LBCL) treated with CD19-directed CAR-T therapy (axi-cel, tisa-cel, or liso-cel) between 2016 and 2023 at a single institution. Cumulative corticosteroid dose was defined as the total dose administered within 21 days of infusion. Corticosteroids were administered to 105 patients (38%), initiated at a median of 5 days post-infusion (interquartile range [IQR] 3-7) for CRS (38%), ICANS (15%), or both (47%). Use was more frequent with axi-cel (P < 0.001), although the cumulative dose and duration were similar across products. To assess the impact of corticosteroid exposure, we carried out a 21-day landmark analysis. Corticosteroid exposure, modeled as a time-dependent covariate, was not significantly associated with infection risk, non-relapse mortality, or inferior overall survival (OS) or progression-free survival (PFS). However, in a landmark analysis, patients receiving above-median cumulative corticosteroid doses had a significantly higher risk of infection compared to those receiving below-median corticosteroid doses or no corticosteroids (P = 0.042). In a landmark multivariable analysis, corticosteroid cumulative dose was associated with increased late hematologic toxicity (adjusted hazard ratio [HR] 1.02, 95% CI 1.02-1.03). Finally, in a sensitivity analysis excluding patients with Grade ≥4 CRS/ICANS, corticosteroid cumulative dose remained unassociated with OS or relapse, but was linked to shorter PFS (adjusted HR 1.04, 95% CI 1.01-1.06). These findings support the safe yet judicious use of corticosteroids to manage CAR-T toxicities in LBCL.

Open article ↗



cell therapies
2026-05-26 | CAR-T cell therapy in cancer immunotherapy – Biology, clinical successes, and emerging challenges: A review

Cancer immunotherapy has transformed oncology by enabling targeted activation of antitumor immune responses in patients with relapsed or refractory malignancies. Among adoptive cell transfer (ACT) strategies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a pivotal therapeutic advancement, genetically redirecting T lymphocytes to recognize tumor-associated antigens independently of major histocompatibility complex (MHC) presentation. This review provides a comprehensive overview of the biological principles, design evolution, manufacturing platforms, clinical applications, resistance mechanisms, toxicities, and future directions of CAR-T cell therapy within cancer immunotherapy. Specifically, we examine the evolution of CAR architecture, spanning from first-generation constructs to advanced armored and fifth-generation platforms. Furthermore, we compare viral and non-viral gene delivery systems and discuss emerging approaches such as in vivo CAR engineering, allogeneic "off-the-shelf" products, logic-gated receptors, safety switches, and alternative immune-cell platforms, including natural killer (NK) cells and macrophages. CAR-T cell therapy has achieved its most profound clinical success in hematological malignancies, particularly in cluster of differentiation 19 (CD19)-positive B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma, reporting durable remission rates of approximately 60-90% in specific clinical contexts. However, broader clinical translation, particularly in solid tumors, remains constrained by challenges such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), antigen escape, tumor heterogeneity, poor trafficking, limited persistence, high manufacturing costs, and the immunosuppressive tumor microenvironment (TME). While next-generation strategies-including clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9)-mediated editing, lipid nanoparticle (LNP)-based messenger ribonucleic acid (mRNA) delivery, bispecific CARs, and inducible suicide switches-hold promise for improving safety, specificity, scalability, and accessibility, a significant number remain in preclinical or early-phase clinical development. Overall, CAR-T cell therapy represents a transformative "living drug" platform in oncology; however, its broader clinical utility is contingent upon improving durability, reducing toxicity, overcoming solid-tumor barriers, and validating next-generation technologies through robust, long-term clinical studies.

Open article ↗



2026-03-27 | Th17-driven CD8+ T cells in hUC-MSC and CAR T-cell dual immunotherapy for superior anti-tumor efficacy

Abstract Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for hematological malignancies; however, its efficacy and safety remain challenging, particularly in the context of high tumor burden. High tumor load and substantial residual lesions significantly impair CAR T-cell function and exacerbate cytokine release syndrome (CRS). Here, we report the development of a novel dual cellular immunotherapy in which human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) are co-administered with CD19 CAR T-cells. We demonstrated that this combination therapy enhances the anti-tumor efficacy of CD19 CAR T-cells under high tumor burden condition. In xenograft models of high tumor burden B-cell lymphoma, the dual cellular immunotherapy improved survival, mitigated myelosuppression, and preserved CAR T-cell expansion. Transcriptomic analysis of CAR T-cells revealed enrichment of the Th17 pathway in CAR T-cells, while single-cell RNA sequencing showed enhanced, particularly that of NK-like cytotoxic T lymphocytes characteristics which are associated with Th17 differentiation. Furthermore, in a CRS model, hUC-MSCs attenuate CRS severity by suppressing macrophage activity. Collectively, hUC-MSCs significantly enhance the anti-tumor capability of CD19 CAR T-cells under high tumor burden conditions by inducing CD8 + NK-like cytotoxic T lymphocytes through Th17 differentiation, while concurrently mitigating treatment-related side effects. Our study provides a novel therapeutic strategy to improve clinical outcomes in hematological malignancies.

Open article ↗



2026-02-03 | Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized the paradigm in hematological malignancies. However, its efficacy in treating solid tumors remains limited because the immunosuppressive tumor microenvironment (ITME) seriously blocks T cell activation, infiltration, and proliferation. Cytokines, driving potent assisted function by enhanced T cell expansion, persistence, and direct tumor cell killing, have long been acknowledged as promising candidates combined with CAR-T cells to improve treatment outcomes. Despite their preclinical success, significant toxicity occurs in up to one-third of patients induced by powerful immune-mediated cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). In these cases, the risk-benefit unbalance is less advantageous for advanced cancer therapies, appealing for a profound understanding of pathophysiological mechanisms of CRS and ICANS, as well as improved management of regulating cytokine production. In this review, we first provide an overview of activation and cytotoxic mechanisms of CAR-T cells. Second, obstacles to CAR-T cells in the ITME are introduced in detail. Third, the advanced design of CAR-T engineered cytokines, coupled with current research progress, is described. Furthermore, pathophysiology and clinical features of CRS and ICANS are described in detail. Lastly, prevention and/or intervention approaches of the two above-mentioned toxicities are emphasized both for developing novel therapeutics and maximizing the benefit of patients.

Open article ↗



2026-01-12 | The “cytokine storm” in infection and sepsis: win the battle but lose the war

The cytokine storm, a life-threatening systemic inflammatory syndrome, is the primary driver of multiorgan failure in different clinical situations, including severe infections, autoimmune diseases, chimeric antigen receptor (CAR) T cell immunotherapy for cancer, and genetic syndromes. This review focuses primarily on cytokine storms triggered by severe infections such as viral pneumonia and bacterial sepsis, and explores the underlying mechanisms of cytokine storms and potential therapeutic interventions. Cytokine storms are characterized primarily by the excessive release of proinflammatory cytokines, which are triggered by pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and PANoptosis, all of which activate immune signaling cascades. Amplification mechanisms involve positive feedback loops and the failure of negative feedback mechanisms, leading to uncontrolled inflammation. Like a pyrrhic victory, the excessive activation of the immune system eliminated invading pathogens but caused catastrophic damage due to multiple organ dysfunction syndrome (MODS), turning the life-saving response into a life-threatening war. Therapeutic strategies, including cytokine antagonists, Janus kinase (JAK) inhibitors, caspase inhibitors, glucocorticoids, and blood purification therapies, aim to interrupt the self-amplifying cycle of inflammation that propagates organ injury, thereby reducing MODS and mortality. Challenges include optimizing the treatment timing and patient stratification. Future research should focus on combination therapies and personalized medicine based on the heterogeneity of infections and sepsis. Advances in multiomics and targeted therapies provide new hope for managing infections and sepsis.

Open article ↗



2026-01-09 | Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial

ABSTRACT: Emerging long-term data indicate relapse rates of >50% after CD19-redirected chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). To reduce selective pressure on the CD19 antigen, we conducted a first-in-human phase 1 clinical trial of zamtocabtagene autoleucel (zamto-cel), a noncryopreserved tandem CD20-CD19-directed CAR T-cell therapy. Two predefined dose levels (dose level 1 [DL1], 1 × 106 and DL2, 2.5 × 106 CAR+ T cells per kg bodyweight) were applied. The primary end point (EP) was the maximum tolerated dose (MTD). Secondary EPs included adverse events, best overall response (BOR), and biomarker assessments. A total of 12 patients, 6 patients per DL, were treated. No dose-limiting toxicity and no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome of grade ≥3 were observed. Thus, MTD was not reached. The BOR by investigator assessment was 75%, with 5 of 12 patients (42%) achieving complete remission (CR) until month 12 with no relapse in clinical evaluation up to 5 years after infusion. CR was associated with a higher mean maximum observed concentration of zamto-cel and detection of zamto-cel beyond month 6. Additional product characterization revealed increased expression of CD27 and CD127 along with increased expansion of CAR+ central memory T cells in patients with CR, facilitating persistence and improved outcomes in R/R B-NHL treated with zamto-cel. Based on the promising risk-to-benefit ratio, evaluation of zamto-cel at DL2 is ongoing in pivotal phase 2 clinical trials for patients with R/R aggressive B-NHL. This trial was registered at www.ClinicalTrials.gov as NCT03870945.

Open article ↗



proteins
2026-06-03 | Managing cytokine release syndrome in hematological malignancies being treated with CAR-T cell therapy

INTRODUCTION: Cytokine release syndrome (CRS) is a potentially life-threatening toxicity associated with chimeric antigen receptor (CAR)-T cell therapy, particularly in hematological malignancies. As CAR-T therapies are increasingly integrated into clinical practice, managing CRS effectively is critical to maximizing therapeutic benefit while minimizing harm. AREAS COVERED: This review provides a comprehensive overview of CRS in the context of CAR-T therapy for hematologic cancers. It outlines the current definitions and grading systems, highlights key aspects of CRS pathophysiology, and analyzes the incidence and severity of CRS across pivotal clinical trials in large B-cell lymphoma, acute lymphoblastic leukemia, and multiple myeloma. Standard management approaches, including anti-cytokine therapies and corticosteroids, are discussed alongside emerging strategies such as early intervention and prophylaxis using anakinra and corticosteroids. The review is informed by a structured evaluation of clinical studies and real-world data, reflecting evolving treatment paradigms. EXPERT OPINION: CRS remains a major challenge, therefore early recognition, standardized grading, and targeted intervention will improve outcomes. Future efforts should focus on predictive biomarkers, personalized prophylaxis, and next-generation CAR constructs to reduce toxicity. The real-world experience mirrors trial data, reinforcing the reproducibility and scalability of these evolving management strategies.

Open article ↗



2026-03-30 | Chimeric antigen receptor T-cell therapies related to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: Diagnosis, high-risk factors, and management

ABSTRACT: Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a life-threatening complication of chimeric antigen receptor T cell (CAR-T) therapy. Despite its high mortality rate, IEC-HS remains underrecognized due to overlapping clinical and laboratory features with severe cytokine release syndrome (CRS), leading to delayed diagnosis and suboptimal management. This review systematically analyzes key strategies to distinguish IEC-HS from severe CRS in the literature. The analysis focuses on temporal patterns, such as the delayed onset of IEC-HS after CAR-T infusion. It also examines dynamic laboratory trends, including persistently elevated ferritin and lactate dehydrogenase levels and a slower decline in C-reactive protein (CRP). In addition, distinct cytokine profiles are discussed, such as prolonged interferon-gamma (IFN-γ) elevation and surges in chemokines and growth factors. We further identify high-risk factors for IEC-HS, including patient-specific factors (baseline inflammation, low natural killer [NK] cell counts), disease-related factors (high B-cell acute lymphoblastic leukemia [B-ALL] burden and prior high-grade CRS), and CAR-T-related factors (CD22 target, CD28 costimulation, T-cell selection, high CAR-T cell dose, excessive CAR-T cell expansion, and TET2 gene mutation). For management, we evaluate conventional therapies (corticosteroids, etoposide) and emerging immunomodulatory agents (anakinra, ruxolitinib, emapalumab), emphasizing the 2023 treatment regimen by the American Society of Transplantation and Cellular Therapy (ASTCT). By integrating risk stratification, early diagnostic criteria, and tailored therapeutic approaches, this review aims to improve clinical outcomes for IEC-HS patients.

Open article ↗



2025-12-30 | Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU

OBJECTIVES: To evaluate evolving management, ICU admission, and outcomes for critically ill chimeric antigen receptor (CAR) T-cell patients over a 6-year period. DESIGN: Multicenter retrospective cohort study from January 2018 to September 2023. SETTING: Eight U.S. centers. PATIENTS: Adult CAR T-cell patients requiring ICU admission. INTERVENTIONS: None. METHODS: Summary statistics included mean, sd , median, and interquartile range (IQR). Fisher exact test or chi-square test were used to evaluate association between year treated and other categorical variables. Cochran-Armitage test was performed to assess significance of trends across years. Multivariable logistic regression was performed to assess covariates associated with mortality. MEASUREMENTS AND MAIN RESULTS: Demographics, toxicity management, ICU admission, support modalities, toxicity severity, and survival (ICU, hospital, and 3-mo) were compared year-to-year. From 2018 to 2023, 2238 patients received CAR T cells, with increasing number of patients treated yearly; 398 (17.8%) required ICU care. Of those admitted to the ICU, 66.1% were male, 89.2% had lymphoma, and median age was 64 years (53-71 yr). ICU admission rates declined from 38.5% (95% CI, 31.6-45.8%) in 2018 to 16.4% in 2023 (95% CI, 13.5-19.7%; p < 0.0001). Cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome was the reason for ICU admission in 87.9%. In 2023 vs. 2018, ICU patients were older (median, 65 yr [IQR, 55-73 yr] vs. 58 yr [48-67 yr]; p = 0.003) with higher comorbidity indices (4 [4-6] vs. 3 [2-4]; p = 0.005) and more severe toxicities (≥ grade 3: 90.1% vs. 69.9%; p = 0.004). Corticosteroid use for less severe toxicities (≤ grade 2 toxicity: 73.8% vs. 40.6%; p = 0.0001) and anakinra use (56% vs. 5.5%; p < 0.0001) increased throughout the years. Mortality from cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome remained low (5.5%). Age, Sequential Organ Failure Assessment greater than or equal to 10 at ICU admission, and ICU admission for noncytokine release/neurotoxicity syndrome reasons were associated with hospital mortality (odds ratios, 1.02 [95% CI, 1-1.04; p = 0.046], 4.69 [2.44-9.01; p < 0.0001], and 3.74 [1.91-7.3; p = 0.0001], respectively). CONCLUSIONS: ICU admission rates after CAR T-cell treatment are declining. Although ICU patients are older with higher severity of illness and toxicity grades, ICU mortality after CAR T-cell therapy remains low.

Open article ↗



2025-12-26 | Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for hematologic malignancies. However, immune effector cell-associated neurotoxicity syndrome (ICANS) remains a significant and potentially lethal complication, affecting approximately 27% to 65% of patients and challenging the therapeutic risk-benefit profile. MAIN BODY: This review synthesizes recent advances in the epidemiology, pathophysiology, diagnosis, and management of ICANS. Incidence varies significantly by product design, with anti-CD19 therapies and CD28-containing constructs demonstrating markedly higher toxicity rates compared to other targets and 4-1BB-based designs. The pathophysiological mechanism centers on blood-brain barrier disruption driven by systemic cytokine release and direct cellular injury. Monocytes and macrophages act as principal effectors, releasing interleukin-1 and granulocyte-macrophage colony-stimulating factor, which trigger endothelial activation and neuroinflammation. Clinical manifestations typically appear within the first week post-infusion, ranging from mild language disturbances to life-threatening cerebral edema. Current management has evolved from reactive symptom control to proactive strategies. Severity-based algorithms guide the use of corticosteroids and intensive care support, while emerging prophylactic approaches, particularly interleukin-1 receptor blockade with anakinra, show promise in reducing severe neurotoxicity without compromising anti-tumor efficacy. Furthermore, diagnostic precision is improving through the use of novel biomarkers, such as chimeric antigen receptor-positive extracellular vesicles, and machine-learning models that predict toxicity days before symptom onset. CONCLUSIONS: The management of ICANS is shifting towards a precision medicine paradigm. By integrating predictive biomarkers, artificial intelligence, and novel prophylactic interventions, clinicians can better stratify risk and implement early treatments. Future research focusing on next-generation constructs with engineered safety features will be essential to decouple therapeutic efficacy from neurotoxicity, ultimately optimizing outcomes for patients with advanced hematologic cancers.

Open article ↗



2025-09-13 | Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy

CD-19 chimeric antigen receptor T-cell therapy (CAR-T) has improved outcomes in relapsed/refractory B-cell malignancies but is associated with cytokine-mediated toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), hematologic toxicities, and infection. Neutropenia is common following CAR-T and varies in duration. Granulocyte colony-stimulating factor (G-CSF) is used to support neutropenia following CAR-T. However, its use within 14 d post-CAR-T is debated due to concerns it may contribute to CRS and ICANS. Data on the efficacy and safety of G-CSF after CAR-T remain inconclusive with no consensus on its use. The objective of this study was to evaluate the difference in CRS or ICANS development and neutropenia outcomes in patients who received G-CSF within 14 d post-CAR-T versus beyond 14 d. This was a retrospective study evaluating patients ≥ 18 yr who received commercial anti-CD-19 CAR-T therapy from December 1, 2019, through June 30, 2024, at Vanderbilt University Medical Center (VUMC) or Veterans Affairs Tennessee Valley Healthcare System (TVHS). Patients were divided into an early cohort (first G-CSF ≤ d +14) and a late/no cohort (first G-CSF > d +14 or none). Primary outcomes were the incidence of CRS and ICANS. Secondary outcomes included severity of CRS and ICANS, duration of neutropenia, and incidence of early (30 d) and late (90 d) neutropenia. Outcomes were compared across early and late/no G-CSF groups with logistic regression or a proportional odds model as appropriate, with propensity score adjustment for treatment center differences. One hundred fifty-seven patients were included in the analysis (61% early, 39% late/no G-CSF). Most patients were white (81%), male (74%) and received axicabtagene ciloleucel (69%). The most common indication for CAR-T cell therapy was diffuse large B-cell lymphoma (69%) after a median of 3 (IQR 2 to 4) prior lines of therapy. The primary outcome of CRS occurred in 92.7% of the early G-CSF group versus 75.4% of the late/no G-CSF group, though the odds were not significantly different in the adjusted analysis (OR 1.92, 95% CI 0.54 to 6.84, P = 0.317). ICANS occurred in 58.3% of early group versus 41.0% of late/no group patients and was also not statistically significant (OR 1.76, 95% CI 0.71 to 4.36, P = 0.223). Although not statistically significant, higher-grade CRS was more likely in the early group (OR 1.93, 95% CI 0.81-4.57, P=0.136). Grade 3 or 4 ICANS occurred in 24.0% of early and 29.5% of late/no G-CSF patients, with no significant difference. Duration of neutropenia in the first 30 d and incidence of early and late neutropenia were similar between groups. Using G-CSF within 14 d post-CAR-T does not increase the risk of CRS or ICANS compared to use after 14 d or no use. The study found no significant difference in severity of CRS or ICANS, duration of neutropenia, or incidence of early and late neutropenia. This questions the utility of G-CSF for CAR-T patients, as it was not shown to improve neutropenia outcomes.

Open article ↗



other
2026-01-27 | In vivo engineering of CAR-T cells: delivery strategies and clinical translation

Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for hematologic malignancies. Nonetheless, its broad clinical adoption is constrained by the logistical, financial, and safety burdens associated with ex vivo cell manufacturing. In vivo CAR-T engineering has emerged as a transformative alternative, enabling the direct reprogramming of endogenous T cells through systemic delivery of CAR-encoding constructs via viral or non-viral vectors. This strategy eliminates the need for leukapheresis, genetic modification, and reinfusion, paving the way for simplified, scalable, and potentially “off-the-shelf” immunotherapies. While challenges such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain shared hurdles, in vivo approaches introduce added complexities, including vector immunogenicity and innate immune sensing. By leveraging RNA-based platforms, in vivo CAR-T engineering is evolving into a programmable immunotherapy modality beyond oncology. At the same time, regulatory frameworks for systemic in vivo reprogramming remain underdeveloped, underscoring the need for harmonized guidelines that balance innovation with patient safety. This review synthesizes progress across major delivery platforms, analyzes key translational and regulatory barriers specific to in vivo approaches, and highlights emerging innovations in vector tropism, immune modulation, and scalable manufacturing. As the field matures, in vivo CAR-T strategies may unlock broader therapeutic applications across oncology and autoimmune disease, redefining the accessibility and precision of cellular immunotherapy.

Open article ↗



antibodies
2026-06-22 | Chimeric antigen receptor-T cell therapy-induced cardiotoxicity: Pathophysiological mechanisms and pharmacological intervention strategies

Chimeric antigen receptor (CAR)-T cell therapy has emerged as a revolutionary treatment for hematologic malignancies and solid tumors. Multiple approved products and ongoing clinical trials have demonstrated its remarkable antitumor efficacy. However, its clinical application is severely limited by prominent cardiotoxicity, which is closely associated with high morbidity and mortality, posing an urgent clinical challenge. This review systematically elucidates the pathophysiological mechanisms underlying CAR-T cell therapy-induced cardiotoxicity, which can be primarily categorized into acute and long-term adverse effects. Acute cardiotoxicity is driven by cytokine release syndrome (CRS) through macrophage and monocyte activation, endothelial dysfunction, and subsequent myocardial injury, leading to hypotension, reduced left ventricular ejection fraction, and cardiac arrhythmias. Long-term cardiotoxicity is mainly caused by B-cell aplasia-induced immune deficiency and secondary hemophagocytic lymphohistiocytosis, which trigger infectious complications, myocardial ischemia, and apoptosis. We have further summarized clinical pharmacological interventions for such cardiotoxicity, including interleukin (IL)-6 receptor antagonists (tocilizumab), interferon-γ inhibitors (emapalumab), and Janus kinase inhibitors (ruxolitinib). However, none of these drugs can completely alleviate CRS or CAR-T cell therapy-induced cardiotoxicity in all patients. Preclinical agents targeting inflammatory cytokines (IL-1β, tumor necrosis factor-α) and signaling pathways have shown efficacy in ameliorating cardiotoxicity in various animal models. These findings provide novel directions and drug candidates for the treatment of CAR-T cell therapy-induced myocardial toxicity. This review provides a comprehensive theoretical basis for optimizing cardiovascular safety management and developing novel targeted interventions for CAR-T cell therapy.

Open article ↗



2026-05-26 | Characterization of CAR-T cell factors that contribute to myeloid cell activation

Chimeric antigen receptor (CAR) T cell therapies have shown remarkable success in the treatment of hematologic cancers; however, their use is often accompanied by inflammatory toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). These toxicities, ranging from mild to life-threatening, are partly driven by bystander myeloid cell activation (BMCA) and the subsequent release of pro-inflammatory cytokines such as IL-6 and IL-1β. Although previous studies have described the individual contributions of GM-CSF, IFN-γ, and TNFα secreted by CAR-T cells, a comprehensive characterization of CAR-T-derived inflammatory factors has been lacking. In this study, we characterized the soluble factors secreted by activated CAR-T cells derived from human peripheral blood and assessed their role in BMCA. Comparative cytokine analyses across human T cell subsets, including CAR-T cells, identified multiple candidates involved in BMCA. Antibody-mediated neutralization confirmed that four factors, GM-CSF, IFN-γ, TNFα, and GPIbα, play dominant roles in driving BMCA. Furthermore, siRNA-mediated knockdown of these factors in CAR-T cells significantly reduced BMCA without impairing their anti-tumor activity. These findings are consistent with prior reports on the inflammatory roles of GM-CSF, IFN-γ, and TNFα during CAR-T cell therapy and, importantly, identify GPIbα as a previously unrecognized contributor to CAR-T-associated inflammatory toxicities. Targeting these factors through antibody blockade or genetic modification may represent a promising strategy to mitigate inflammatory toxicities and improve the safety of CAR-T cell therapies.

Open article ↗



2026-03-04 | Emapalumab in pediatric patients with high-grade cytokine release syndrome associated with CAR T-cell therapy

Background Chimeric antigen receptor T (CAR-T) cell therapy significantly improves the prognosis of a variety of hematological malignancies; however, its broader application in clinical practice is hindered by adverse events, particularly cytokine release syndrome (CRS). Moreover, the selection of treatment strategies for patients with high-grade CRS must be meticulously tailored. Emapalumab, a fully human IgG1 monoclonal antibody targeting IFN-γ, has been proposed to have clinical benefit in CRS. Methods In this retrospective study, we conducted a comprehensive analysis of clinical and laboratory parameters in 38 pediatric patients who failed low-dose glucocorticoids monotherapy, tocilizumab monotherapy or glucocorticoid-tocilizumab combination therapy, following treatment with investigational CAR-T products. Results Emapalumab significantly improved both clinical symptoms and laboratory parameters. The rapid decrease in mean temperature (39.61 vs. 38.38°C, P &lt; 0.001) and levels of inflammatory markers including IL-2 (32.35 vs. 11.94 pg/ml, P &lt; 0.001), IL-10 (222.29 vs. 86.09 pg/ml, P = 0.018), TNF-α (4.17 vs. 2.94 pg/ml, P = 0.032), and IFN-γ (21984.11 vs. 674.87 pg/ml, P &lt; 0.001) indicated the remarkable scavenging efficacy of emapalumab against cytokine storm following CAR-T therapy. Additionally, both mean CAR-T cell counts (549.95 vs. 8.16 cell/μl, P &lt; 0.001) and the ratio of CAR-T to CD3+ (11.3% vs. 36.54%, P &lt; 0.001) in peripheral blood increased significantly, demonstrating that the administration of emapalumab didn’t seem to have a significant negative impact on the proliferation of CAR-T cells. The median EFS and OS were both not reached, with an EFS rate of 76.9% (95%CI, 63.8-92.6) and with an OS rate of 80.1% (95% CI, 67.7-94.6) at 6 months. Throughout the treatment course, no direct evidence of emapalumab-related safety risks was observed. Conclusion Emapalumab seems to serve as an effective salvage therapy for patients experiencing high-grade CRS with inadequate response to low-dose glucocorticoids and/or tocilizumab following CAR-T therapy. These data supported the use of emapalumab in high-grade CRS as well as provide rationale for future prospective studies.

Open article ↗



2026-02-27 | CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma in a nonagenarian patient

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the management of relapsed/refractory large B-cell lymphoma. However, evidence in the ultra-elderly population remains scarce. We report a 90-year-old woman with relapsed/refractory diffuse large B-cell lymphoma transformed from follicular lymphoma who received lisocabtagene maraleucel. Despite advanced age, preserved cognition, intact instrumental activities of daily living, and acceptable organ reserve supported her candidacy for CAR T-cell therapy. Cytokine release syndrome (CRS) developed as grade 1 (day 1, 38.0 °C) and grade 2 (day 3, hypoxemia to 6 L/min), which resolved after early tocilizumab and dexamethasone. No immune effector cell-associated neurotoxicity syndrome or infectious complications occurred. Grade 2-4 cytopenia persisted transiently but was managed with supportive care, and she was discharged on day 28. To our knowledge, this represents the first reported case of a nonagenarian Asian patient successfully treated with CAR T-cell therapy, highlighting the feasibility and tolerability of this approach and emphasizing the importance of geriatric assessment and prompt CRS management for safe delivery in the very elderly.

Open article ↗



2026-01-01 | Fanning the flames: IFN-γ fuels CAR-T inflammation and cytopenia

Chimeric antigen receptor T cell (CAR-T) therapy has transformed the treatment of hematologic malignancies, yet, severe inflammatory toxicities continue to limit its broader use. In this issue of the JCI, Goala et al. uncovered a mechanistic link between IFN-γ-driven inflammation and disrupted neutrophil homeostasis, revealing that cytokine release syndrome (CRS) and immune cell-associated hematologic toxicity (ICAHT) stem from a shared biological pathway. Using IL-2Ra-deficient mice and patient samples, they showed that IFN-γ suppressed IL-17A and granulocyte colony-stimulating factor (G-CSF), disrupting granulopoiesis and neutrophil survival. Strikingly, IFN-γ blockade eased both CRS and neutropenia without diminishing CAR-T efficacy, suggesting a path toward safer, better-tolerated cell therapies.

Open article ↗



small molecules
2026-05-05 | Extracorporeal blood purification in the management of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a case report

Chimeric antigen receptor T-cell (CAR-T) therapy is associated with potentially severe toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). We report a case of a 32-year-old man with refractory diffuse large B-cell lymphoma who developed severe ICANS after axicabtagene ciloleucel infusion despite standard treatment with corticosteroids, tocilizumab, anakinra, and supportive therapy. Because of rapid clinical deterioration, extracorporeal blood purification with CytoSorb was initiated. The treatment was followed by rapid neurological and hemodynamic improvement, reduction of inflammatory markers, and transfer from the intensive care unit to the hematology ward. CAR-T cell expansion, monitored by droplet digital PCR, was preserved after cytokine adsorption. This case suggests that extracorporeal blood purification may be a feasible rescue strategy for severe CAR-T-related neurotoxicity without compromising CAR-T cell activity.

Open article ↗



2026-03-12 | The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy

Chimeric antigen receptor T (CAR T)-cell therapy is revolutionizing cancer treatment in hematologic malignancies, but challenges related to the tumor microenvironment have hindered CAR T success, especially in solid tumors. Myeloid cells in particular have been implicated in CAR T efficacy. In this review, we discuss the roles of myeloid cells in CAR T-associated toxicities, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, along with strategies to treat these toxicities by modulating myeloid cells. The review also explores myeloid cell-mediated suppression or enhancement of CAR T function. Finally, strategies used to target myeloid cells in combination with CAR T-cell therapy will be investigated.

Open article ↗



2026-01-01 | Next-generation CAR-T combinations: Integrating nanomedicine, metabolic reprogramming, and AI for solid tumor targeting

Background Chimeric Antigen Receptor (CAR)-T cell therapy has demonstrated remarkable clinical success in hematological malignancies; however, its translation to solid tumors remains limited due to the hostile tumor microenvironment (TME), characterized by physical barriers, immunosuppression, metabolic competition, and treatment-limiting toxicities such as Cytokine Release Syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Purpose This review aims to critically evaluate next-generation combination strategies that enhance CAR-T efficacy in solid tumors, with particular emphasis on phytochemicals and natural small molecules as immunometabolic modulators within multimodal therapeutic frameworks. Study Design This is a narrative and mechanism-oriented review integrating evidence from immunotherapy, pharmacology, nanomedicine, and computational biology. Methods Relevant literature was systematically examined to analyze emerging approaches that combine CAR-T therapy with nanotechnology-enabled delivery systems, phytochemical-based metabolic modulation, and artificial intelligence-driven network pharmacology. Mechanistic pathways including AMPK-mTOR-SIRT1 signaling, NF-κB activation, STAT3 signaling, and NLRP3 inflammasome regulation were evaluated in the context of CAR-T persistence, metabolic fitness, and toxicity mitigation. Results Evidence indicates that localized nanotechnology platforms such as “backpack” nanoparticles improve CAR-T trafficking and reduce systemic toxicity. Phytochemicals including resveratrol, berberine, curcumin, and baicalin function as metabolic regulators that promote mitochondrial fitness, shift T-cell metabolism toward oxidative phosphorylation, and attenuate hyperinflammatory signaling underlying CRS. Artificial intelligence and network pharmacology approaches further enable rational identification of synergistic combinations and predictive responder stratification. Conclusion Multimodal precision strategies integrating nanotechnology, phytochemical immunometabolic modulation, and computational design represent promising avenues to overcome solid tumor resistance to CAR-T therapy. Repositioning natural small molecules as mechanistic immunopharmacological adjuvants may enhance therapeutic durability while reducing toxicity, supporting their translational potential in solid tumor immunotherapy.

Open article ↗



2025-11-02 | High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T)

Background: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated substantial efficacy in relapsed and/or refractory multiple myeloma. While toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) have been well characterized, the incidence and clinical consequences of the coagulopathy associated with CRS remain underexplored. Methods: We conducted a prospective analysis of 108 adult patients with multiple myeloma or light chain amyloidosis treated with the academic anti-BCMA CAR-T HBI0101 in a single-center trial (NCT04720313). Coagulopathy was evaluated via serial fibrinogen measurements, with hypofibrinogenemia defined as <200 mg/dL and severe coagulopathy as <100 mg/dL. Laboratory markers, tocilizumab and blood product use, and thrombotic and bleeding complications were recorded. Patients received a short (3-day) or extended course of enoxaparin thromboprophylaxis as well as fresh frozen plasma in cases of severe coagulopathy. Results: CRS grades 1-3 occurred in 100 patients (93%). Hypofibrinogenemia was observed in 79 patients (73%), including 20 (19%) with severe coagulopathy. Fibrinogen levels were significantly associated with CRS severity (p < 0.001), number of tocilizumab doses (p < 0.001), peak levels of the inflammation markers LDH (p = 0.001) and ferritin (p = 0.006), and neutropenia (p = 0.33). Five thrombotic events (4.6%) and three minor bleeding events (2.7%) occurred within 3 months post-CAR-T infusion and were not associated with degree of coagulopathy or CRS. No cases of major bleeding or fatal thrombosis occurred. Conclusions: CRS-related coagulopathy is common following BCMA-targeted CAR-T treatment and correlates closely with CRS severity. Despite the high rate of laboratory coagulopathy, thrombosis and bleeding events were infrequent, suggesting the benefit of the prophylactic strategies used.

Open article ↗



2025-11-01 | Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma

Corticosteroids are commonly used to manage cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor (CAR) T-cell therapy, and yet, their dose-specific impact on outcomes remains uncertain. We retrospectively evaluated 276 adults with large B-cell lymphoma (LBCL) treated with CD19-directed CAR-T therapy (axi-cel, tisa-cel, or liso-cel) between 2016 and 2023 at a single institution. Cumulative corticosteroid dose was defined as the total dose administered within 21 days of infusion. Corticosteroids were administered to 105 patients (38%), initiated at a median of 5 days post-infusion (interquartile range [IQR] 3-7) for CRS (38%), ICANS (15%), or both (47%). Use was more frequent with axi-cel (P < 0.001), although the cumulative dose and duration were similar across products. To assess the impact of corticosteroid exposure, we carried out a 21-day landmark analysis. Corticosteroid exposure, modeled as a time-dependent covariate, was not significantly associated with infection risk, non-relapse mortality, or inferior overall survival (OS) or progression-free survival (PFS). However, in a landmark analysis, patients receiving above-median cumulative corticosteroid doses had a significantly higher risk of infection compared to those receiving below-median corticosteroid doses or no corticosteroids (P = 0.042). In a landmark multivariable analysis, corticosteroid cumulative dose was associated with increased late hematologic toxicity (adjusted hazard ratio [HR] 1.02, 95% CI 1.02-1.03). Finally, in a sensitivity analysis excluding patients with Grade ≥4 CRS/ICANS, corticosteroid cumulative dose remained unassociated with OS or relapse, but was linked to shorter PFS (adjusted HR 1.04, 95% CI 1.01-1.06). These findings support the safe yet judicious use of corticosteroids to manage CAR-T toxicities in LBCL.

Open article ↗



cell therapies
2026-05-26 | CAR-T cell therapy in cancer immunotherapy – Biology, clinical successes, and emerging challenges: A review

Cancer immunotherapy has transformed oncology by enabling targeted activation of antitumor immune responses in patients with relapsed or refractory malignancies. Among adoptive cell transfer (ACT) strategies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a pivotal therapeutic advancement, genetically redirecting T lymphocytes to recognize tumor-associated antigens independently of major histocompatibility complex (MHC) presentation. This review provides a comprehensive overview of the biological principles, design evolution, manufacturing platforms, clinical applications, resistance mechanisms, toxicities, and future directions of CAR-T cell therapy within cancer immunotherapy. Specifically, we examine the evolution of CAR architecture, spanning from first-generation constructs to advanced armored and fifth-generation platforms. Furthermore, we compare viral and non-viral gene delivery systems and discuss emerging approaches such as in vivo CAR engineering, allogeneic "off-the-shelf" products, logic-gated receptors, safety switches, and alternative immune-cell platforms, including natural killer (NK) cells and macrophages. CAR-T cell therapy has achieved its most profound clinical success in hematological malignancies, particularly in cluster of differentiation 19 (CD19)-positive B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma, reporting durable remission rates of approximately 60-90% in specific clinical contexts. However, broader clinical translation, particularly in solid tumors, remains constrained by challenges such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), antigen escape, tumor heterogeneity, poor trafficking, limited persistence, high manufacturing costs, and the immunosuppressive tumor microenvironment (TME). While next-generation strategies-including clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9)-mediated editing, lipid nanoparticle (LNP)-based messenger ribonucleic acid (mRNA) delivery, bispecific CARs, and inducible suicide switches-hold promise for improving safety, specificity, scalability, and accessibility, a significant number remain in preclinical or early-phase clinical development. Overall, CAR-T cell therapy represents a transformative "living drug" platform in oncology; however, its broader clinical utility is contingent upon improving durability, reducing toxicity, overcoming solid-tumor barriers, and validating next-generation technologies through robust, long-term clinical studies.

Open article ↗



2026-03-27 | Th17-driven CD8+ T cells in hUC-MSC and CAR T-cell dual immunotherapy for superior anti-tumor efficacy

Abstract Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for hematological malignancies; however, its efficacy and safety remain challenging, particularly in the context of high tumor burden. High tumor load and substantial residual lesions significantly impair CAR T-cell function and exacerbate cytokine release syndrome (CRS). Here, we report the development of a novel dual cellular immunotherapy in which human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) are co-administered with CD19 CAR T-cells. We demonstrated that this combination therapy enhances the anti-tumor efficacy of CD19 CAR T-cells under high tumor burden condition. In xenograft models of high tumor burden B-cell lymphoma, the dual cellular immunotherapy improved survival, mitigated myelosuppression, and preserved CAR T-cell expansion. Transcriptomic analysis of CAR T-cells revealed enrichment of the Th17 pathway in CAR T-cells, while single-cell RNA sequencing showed enhanced, particularly that of NK-like cytotoxic T lymphocytes characteristics which are associated with Th17 differentiation. Furthermore, in a CRS model, hUC-MSCs attenuate CRS severity by suppressing macrophage activity. Collectively, hUC-MSCs significantly enhance the anti-tumor capability of CD19 CAR T-cells under high tumor burden conditions by inducing CD8 + NK-like cytotoxic T lymphocytes through Th17 differentiation, while concurrently mitigating treatment-related side effects. Our study provides a novel therapeutic strategy to improve clinical outcomes in hematological malignancies.

Open article ↗



2026-02-03 | Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized the paradigm in hematological malignancies. However, its efficacy in treating solid tumors remains limited because the immunosuppressive tumor microenvironment (ITME) seriously blocks T cell activation, infiltration, and proliferation. Cytokines, driving potent assisted function by enhanced T cell expansion, persistence, and direct tumor cell killing, have long been acknowledged as promising candidates combined with CAR-T cells to improve treatment outcomes. Despite their preclinical success, significant toxicity occurs in up to one-third of patients induced by powerful immune-mediated cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). In these cases, the risk-benefit unbalance is less advantageous for advanced cancer therapies, appealing for a profound understanding of pathophysiological mechanisms of CRS and ICANS, as well as improved management of regulating cytokine production. In this review, we first provide an overview of activation and cytotoxic mechanisms of CAR-T cells. Second, obstacles to CAR-T cells in the ITME are introduced in detail. Third, the advanced design of CAR-T engineered cytokines, coupled with current research progress, is described. Furthermore, pathophysiology and clinical features of CRS and ICANS are described in detail. Lastly, prevention and/or intervention approaches of the two above-mentioned toxicities are emphasized both for developing novel therapeutics and maximizing the benefit of patients.

Open article ↗



2026-01-12 | The “cytokine storm” in infection and sepsis: win the battle but lose the war

The cytokine storm, a life-threatening systemic inflammatory syndrome, is the primary driver of multiorgan failure in different clinical situations, including severe infections, autoimmune diseases, chimeric antigen receptor (CAR) T cell immunotherapy for cancer, and genetic syndromes. This review focuses primarily on cytokine storms triggered by severe infections such as viral pneumonia and bacterial sepsis, and explores the underlying mechanisms of cytokine storms and potential therapeutic interventions. Cytokine storms are characterized primarily by the excessive release of proinflammatory cytokines, which are triggered by pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and PANoptosis, all of which activate immune signaling cascades. Amplification mechanisms involve positive feedback loops and the failure of negative feedback mechanisms, leading to uncontrolled inflammation. Like a pyrrhic victory, the excessive activation of the immune system eliminated invading pathogens but caused catastrophic damage due to multiple organ dysfunction syndrome (MODS), turning the life-saving response into a life-threatening war. Therapeutic strategies, including cytokine antagonists, Janus kinase (JAK) inhibitors, caspase inhibitors, glucocorticoids, and blood purification therapies, aim to interrupt the self-amplifying cycle of inflammation that propagates organ injury, thereby reducing MODS and mortality. Challenges include optimizing the treatment timing and patient stratification. Future research should focus on combination therapies and personalized medicine based on the heterogeneity of infections and sepsis. Advances in multiomics and targeted therapies provide new hope for managing infections and sepsis.

Open article ↗



2026-01-09 | Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial

ABSTRACT: Emerging long-term data indicate relapse rates of >50% after CD19-redirected chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). To reduce selective pressure on the CD19 antigen, we conducted a first-in-human phase 1 clinical trial of zamtocabtagene autoleucel (zamto-cel), a noncryopreserved tandem CD20-CD19-directed CAR T-cell therapy. Two predefined dose levels (dose level 1 [DL1], 1 × 106 and DL2, 2.5 × 106 CAR+ T cells per kg bodyweight) were applied. The primary end point (EP) was the maximum tolerated dose (MTD). Secondary EPs included adverse events, best overall response (BOR), and biomarker assessments. A total of 12 patients, 6 patients per DL, were treated. No dose-limiting toxicity and no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome of grade ≥3 were observed. Thus, MTD was not reached. The BOR by investigator assessment was 75%, with 5 of 12 patients (42%) achieving complete remission (CR) until month 12 with no relapse in clinical evaluation up to 5 years after infusion. CR was associated with a higher mean maximum observed concentration of zamto-cel and detection of zamto-cel beyond month 6. Additional product characterization revealed increased expression of CD27 and CD127 along with increased expansion of CAR+ central memory T cells in patients with CR, facilitating persistence and improved outcomes in R/R B-NHL treated with zamto-cel. Based on the promising risk-to-benefit ratio, evaluation of zamto-cel at DL2 is ongoing in pivotal phase 2 clinical trials for patients with R/R aggressive B-NHL. This trial was registered at www.ClinicalTrials.gov as NCT03870945.

Open article ↗



proteins
2026-06-03 | Managing cytokine release syndrome in hematological malignancies being treated with CAR-T cell therapy

INTRODUCTION: Cytokine release syndrome (CRS) is a potentially life-threatening toxicity associated with chimeric antigen receptor (CAR)-T cell therapy, particularly in hematological malignancies. As CAR-T therapies are increasingly integrated into clinical practice, managing CRS effectively is critical to maximizing therapeutic benefit while minimizing harm. AREAS COVERED: This review provides a comprehensive overview of CRS in the context of CAR-T therapy for hematologic cancers. It outlines the current definitions and grading systems, highlights key aspects of CRS pathophysiology, and analyzes the incidence and severity of CRS across pivotal clinical trials in large B-cell lymphoma, acute lymphoblastic leukemia, and multiple myeloma. Standard management approaches, including anti-cytokine therapies and corticosteroids, are discussed alongside emerging strategies such as early intervention and prophylaxis using anakinra and corticosteroids. The review is informed by a structured evaluation of clinical studies and real-world data, reflecting evolving treatment paradigms. EXPERT OPINION: CRS remains a major challenge, therefore early recognition, standardized grading, and targeted intervention will improve outcomes. Future efforts should focus on predictive biomarkers, personalized prophylaxis, and next-generation CAR constructs to reduce toxicity. The real-world experience mirrors trial data, reinforcing the reproducibility and scalability of these evolving management strategies.

Open article ↗



2026-03-30 | Chimeric antigen receptor T-cell therapies related to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: Diagnosis, high-risk factors, and management

ABSTRACT: Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a life-threatening complication of chimeric antigen receptor T cell (CAR-T) therapy. Despite its high mortality rate, IEC-HS remains underrecognized due to overlapping clinical and laboratory features with severe cytokine release syndrome (CRS), leading to delayed diagnosis and suboptimal management. This review systematically analyzes key strategies to distinguish IEC-HS from severe CRS in the literature. The analysis focuses on temporal patterns, such as the delayed onset of IEC-HS after CAR-T infusion. It also examines dynamic laboratory trends, including persistently elevated ferritin and lactate dehydrogenase levels and a slower decline in C-reactive protein (CRP). In addition, distinct cytokine profiles are discussed, such as prolonged interferon-gamma (IFN-γ) elevation and surges in chemokines and growth factors. We further identify high-risk factors for IEC-HS, including patient-specific factors (baseline inflammation, low natural killer [NK] cell counts), disease-related factors (high B-cell acute lymphoblastic leukemia [B-ALL] burden and prior high-grade CRS), and CAR-T-related factors (CD22 target, CD28 costimulation, T-cell selection, high CAR-T cell dose, excessive CAR-T cell expansion, and TET2 gene mutation). For management, we evaluate conventional therapies (corticosteroids, etoposide) and emerging immunomodulatory agents (anakinra, ruxolitinib, emapalumab), emphasizing the 2023 treatment regimen by the American Society of Transplantation and Cellular Therapy (ASTCT). By integrating risk stratification, early diagnostic criteria, and tailored therapeutic approaches, this review aims to improve clinical outcomes for IEC-HS patients.

Open article ↗



2025-12-30 | Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU

OBJECTIVES: To evaluate evolving management, ICU admission, and outcomes for critically ill chimeric antigen receptor (CAR) T-cell patients over a 6-year period. DESIGN: Multicenter retrospective cohort study from January 2018 to September 2023. SETTING: Eight U.S. centers. PATIENTS: Adult CAR T-cell patients requiring ICU admission. INTERVENTIONS: None. METHODS: Summary statistics included mean, sd , median, and interquartile range (IQR). Fisher exact test or chi-square test were used to evaluate association between year treated and other categorical variables. Cochran-Armitage test was performed to assess significance of trends across years. Multivariable logistic regression was performed to assess covariates associated with mortality. MEASUREMENTS AND MAIN RESULTS: Demographics, toxicity management, ICU admission, support modalities, toxicity severity, and survival (ICU, hospital, and 3-mo) were compared year-to-year. From 2018 to 2023, 2238 patients received CAR T cells, with increasing number of patients treated yearly; 398 (17.8%) required ICU care. Of those admitted to the ICU, 66.1% were male, 89.2% had lymphoma, and median age was 64 years (53-71 yr). ICU admission rates declined from 38.5% (95% CI, 31.6-45.8%) in 2018 to 16.4% in 2023 (95% CI, 13.5-19.7%; p < 0.0001). Cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome was the reason for ICU admission in 87.9%. In 2023 vs. 2018, ICU patients were older (median, 65 yr [IQR, 55-73 yr] vs. 58 yr [48-67 yr]; p = 0.003) with higher comorbidity indices (4 [4-6] vs. 3 [2-4]; p = 0.005) and more severe toxicities (≥ grade 3: 90.1% vs. 69.9%; p = 0.004). Corticosteroid use for less severe toxicities (≤ grade 2 toxicity: 73.8% vs. 40.6%; p = 0.0001) and anakinra use (56% vs. 5.5%; p < 0.0001) increased throughout the years. Mortality from cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome remained low (5.5%). Age, Sequential Organ Failure Assessment greater than or equal to 10 at ICU admission, and ICU admission for noncytokine release/neurotoxicity syndrome reasons were associated with hospital mortality (odds ratios, 1.02 [95% CI, 1-1.04; p = 0.046], 4.69 [2.44-9.01; p < 0.0001], and 3.74 [1.91-7.3; p = 0.0001], respectively). CONCLUSIONS: ICU admission rates after CAR T-cell treatment are declining. Although ICU patients are older with higher severity of illness and toxicity grades, ICU mortality after CAR T-cell therapy remains low.

Open article ↗



2025-12-26 | Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for hematologic malignancies. However, immune effector cell-associated neurotoxicity syndrome (ICANS) remains a significant and potentially lethal complication, affecting approximately 27% to 65% of patients and challenging the therapeutic risk-benefit profile. MAIN BODY: This review synthesizes recent advances in the epidemiology, pathophysiology, diagnosis, and management of ICANS. Incidence varies significantly by product design, with anti-CD19 therapies and CD28-containing constructs demonstrating markedly higher toxicity rates compared to other targets and 4-1BB-based designs. The pathophysiological mechanism centers on blood-brain barrier disruption driven by systemic cytokine release and direct cellular injury. Monocytes and macrophages act as principal effectors, releasing interleukin-1 and granulocyte-macrophage colony-stimulating factor, which trigger endothelial activation and neuroinflammation. Clinical manifestations typically appear within the first week post-infusion, ranging from mild language disturbances to life-threatening cerebral edema. Current management has evolved from reactive symptom control to proactive strategies. Severity-based algorithms guide the use of corticosteroids and intensive care support, while emerging prophylactic approaches, particularly interleukin-1 receptor blockade with anakinra, show promise in reducing severe neurotoxicity without compromising anti-tumor efficacy. Furthermore, diagnostic precision is improving through the use of novel biomarkers, such as chimeric antigen receptor-positive extracellular vesicles, and machine-learning models that predict toxicity days before symptom onset. CONCLUSIONS: The management of ICANS is shifting towards a precision medicine paradigm. By integrating predictive biomarkers, artificial intelligence, and novel prophylactic interventions, clinicians can better stratify risk and implement early treatments. Future research focusing on next-generation constructs with engineered safety features will be essential to decouple therapeutic efficacy from neurotoxicity, ultimately optimizing outcomes for patients with advanced hematologic cancers.

Open article ↗



2025-09-13 | Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy

CD-19 chimeric antigen receptor T-cell therapy (CAR-T) has improved outcomes in relapsed/refractory B-cell malignancies but is associated with cytokine-mediated toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), hematologic toxicities, and infection. Neutropenia is common following CAR-T and varies in duration. Granulocyte colony-stimulating factor (G-CSF) is used to support neutropenia following CAR-T. However, its use within 14 d post-CAR-T is debated due to concerns it may contribute to CRS and ICANS. Data on the efficacy and safety of G-CSF after CAR-T remain inconclusive with no consensus on its use. The objective of this study was to evaluate the difference in CRS or ICANS development and neutropenia outcomes in patients who received G-CSF within 14 d post-CAR-T versus beyond 14 d. This was a retrospective study evaluating patients ≥ 18 yr who received commercial anti-CD-19 CAR-T therapy from December 1, 2019, through June 30, 2024, at Vanderbilt University Medical Center (VUMC) or Veterans Affairs Tennessee Valley Healthcare System (TVHS). Patients were divided into an early cohort (first G-CSF ≤ d +14) and a late/no cohort (first G-CSF > d +14 or none). Primary outcomes were the incidence of CRS and ICANS. Secondary outcomes included severity of CRS and ICANS, duration of neutropenia, and incidence of early (30 d) and late (90 d) neutropenia. Outcomes were compared across early and late/no G-CSF groups with logistic regression or a proportional odds model as appropriate, with propensity score adjustment for treatment center differences. One hundred fifty-seven patients were included in the analysis (61% early, 39% late/no G-CSF). Most patients were white (81%), male (74%) and received axicabtagene ciloleucel (69%). The most common indication for CAR-T cell therapy was diffuse large B-cell lymphoma (69%) after a median of 3 (IQR 2 to 4) prior lines of therapy. The primary outcome of CRS occurred in 92.7% of the early G-CSF group versus 75.4% of the late/no G-CSF group, though the odds were not significantly different in the adjusted analysis (OR 1.92, 95% CI 0.54 to 6.84, P = 0.317). ICANS occurred in 58.3% of early group versus 41.0% of late/no group patients and was also not statistically significant (OR 1.76, 95% CI 0.71 to 4.36, P = 0.223). Although not statistically significant, higher-grade CRS was more likely in the early group (OR 1.93, 95% CI 0.81-4.57, P=0.136). Grade 3 or 4 ICANS occurred in 24.0% of early and 29.5% of late/no G-CSF patients, with no significant difference. Duration of neutropenia in the first 30 d and incidence of early and late neutropenia were similar between groups. Using G-CSF within 14 d post-CAR-T does not increase the risk of CRS or ICANS compared to use after 14 d or no use. The study found no significant difference in severity of CRS or ICANS, duration of neutropenia, or incidence of early and late neutropenia. This questions the utility of G-CSF for CAR-T patients, as it was not shown to improve neutropenia outcomes.

Open article ↗



other
2026-01-27 | In vivo engineering of CAR-T cells: delivery strategies and clinical translation

Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for hematologic malignancies. Nonetheless, its broad clinical adoption is constrained by the logistical, financial, and safety burdens associated with ex vivo cell manufacturing. In vivo CAR-T engineering has emerged as a transformative alternative, enabling the direct reprogramming of endogenous T cells through systemic delivery of CAR-encoding constructs via viral or non-viral vectors. This strategy eliminates the need for leukapheresis, genetic modification, and reinfusion, paving the way for simplified, scalable, and potentially “off-the-shelf” immunotherapies. While challenges such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain shared hurdles, in vivo approaches introduce added complexities, including vector immunogenicity and innate immune sensing. By leveraging RNA-based platforms, in vivo CAR-T engineering is evolving into a programmable immunotherapy modality beyond oncology. At the same time, regulatory frameworks for systemic in vivo reprogramming remain underdeveloped, underscoring the need for harmonized guidelines that balance innovation with patient safety. This review synthesizes progress across major delivery platforms, analyzes key translational and regulatory barriers specific to in vivo approaches, and highlights emerging innovations in vector tropism, immune modulation, and scalable manufacturing. As the field matures, in vivo CAR-T strategies may unlock broader therapeutic applications across oncology and autoimmune disease, redefining the accessibility and precision of cellular immunotherapy.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

1 orphan drug designation for CAR T cell therapy-associated cytokine release syndrome, including 1 approved therapy.

1 orphan drug designation for CAR T cell therapy-associated cytokine release syndrome, including 1 approved therapy.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

tocilizumab [Actemra]

antibodies

FDA
2017-08-01

Approved
2017-08-30

Genentech Inc., a member of the Roche Group

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.